Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
Xin Huang, Weiyue Zhang, Zhicai Zhang, Deyao Shi, Fashuai Wu, Binlong Zhong, Zengwu Shao · Journal of Cancer · 2018
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · review · 2018
Abstract
Purpose: Programmed cell death 1 ligand-1 (PD-L1) and PD-1 as prognostic biomarkers have spurred considerable interest in several types of malignant tumors.In the present meta-analysis, we aimed to elucidate the clinicopathological and prognostic values of PD-L1/PD-1 in osteosarcoma.Methods: We systematically searched PubMed, Web of Science, EMBASE, Scopus, CBM and the Cochrane Library databases up to March 3, 2018.Eligible studies assessing the relationship between PD-L1 or PD-1 expression and clinicopathological and prognostic outcomes in osteosarcoma were incorporated.Pooled relative risks (RRs) and 95% confidence intervals (CIs) were used to estimate the outcomes.Results: Eight studies involving 413 patients were incorporated into our meta-analysis.Pooled results showed that PD-L1/PD-1 overexpression was significantly associated with metastasis (RR = 1.54, 95% CI: 1.12-2.11,p = 0.008) in osteosarcoma.Furthermore, osteosarcoma patients exhibited a remarkably higher total mortality risk (RR = 1.86, 95% CI: 1.09-3.17,p = 0.021) with PD-L1/PD-1 overexpression.However, no significant reduced overall survival rate (RR = 0.70, 95% CI: 0.46-1.07,p = 0.103) was detected in the study.Conclusion: Our meta-analysis indicates that PD-L1/PD-1 may serve as an important biomarker for adverse clinicopathologic features and poor prognosis in patients with osteosarcoma.
Open the resolved locator · 10.7150/jca.25011
Metadata licence: OpenAlex metadata (CC0)